| Implications for immunosurveillance of altered HLA class I phenotypes in human tumours F Garrido, F Ruiz-Cabello, T Cabrera, JJ Perez-Villar, M López-Botet, ... Immunology today 18 (2), 89-95, 1997 | 1040 | 1997 |
| MHC class I antigens, immune surveillance, and tumor immune escape A Garcia‐Lora, I Algarra, F Garrido Journal of cellular physiology 195 (3), 346-355, 2003 | 668 | 2003 |
| The urgent need to recover MHC class I in cancers for effective immunotherapy F Garrido, N Aptsiauri, EM Doorduijn, AMG Lora, T Van Hall Current opinion in immunology 39, 44-51, 2016 | 658 | 2016 |
| Natural history of HLA expression during tumour development F Garrido, T Cabrera, A Concha, S Glew, F Ruiz-Cabello, PL Stern Immunology today 14 (10), 491-499, 1993 | 603 | 1993 |
| The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape I Algarra, A García-Lora, T Cabrera, F Ruiz-Cabello, F Garrido Cancer Immunology, Immunotherapy 53, 904-910, 2004 | 394 | 2004 |
| MHC antigens and tumor escape from immune surveillance F Garrido, I Algarra Academic Press 83, 117-158, 2001 | 394 | 2001 |
| “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy F Garrido, T Cabrera, N Aptsiauri International journal of cancer 127 (2), 249-256, 2010 | 346 | 2010 |
| Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors S Rusakiewicz, M Semeraro, M Sarabi, M Desbois, C Locher, R Mendez, ... Cancer research 73 (12), 3499-3510, 2013 | 341 | 2013 |
| HLA class I antigen abnormalities and immune escape by malignant cells B Seliger, T Cabrera, F Garrido, S Ferrone Seminars in cancer biology 12 (1), 3-13, 2002 | 336 | 2002 |
| A new extract of the plant calendula officinalis produces a dual in vitroeffect: cytotoxic anti-tumor activity and lymphocyte activation E Jiménez-Medina, A Garcia-Lora, L Paco, I Algarra, A Collado, F Garrido BMC câncer 6, 1-14, 2006 | 305 | 2006 |
| Rexpression of HLA class I antigens and restoration of antigen‐specific CTL response in melanoma cells following 5‐aza‐2′‐deoxycytidine treatment A Serrano, S Tanzarella, I Lionello, R Mendez, C Traversari, ... International journal of cancer 94 (2), 243-251, 2001 | 293 | 2001 |
| The HLA crossroad in tumor immunology I Algarra, T Cabrera, F Garrido Human immunology 61 (1), 65-73, 2000 | 246 | 2000 |
| Analysis of HLA-E expression in human tumors R Marín, F Ruiz-Cabello, S Pedrinaci, R Méndez, P Jiménez, ... Immunogenetics 54, 767-775, 2003 | 233 | 2003 |
| High frequency of altered HLA class I phenotypes in invasive breast carcinomas T Cabrera, MA Fernandez, A Sierra, A Garrido, A Herruzo, A Escobedo, ... Human immunology 50 (2), 127-134, 1996 | 217 | 1996 |
| Further evidence for derepression of H–2 and Ia-like specificities of foreign haplotypes in mouse tumour cell lines F Garrido, H Festenstein, V Schirrmacher Nature 261 (5562), 705-707, 1976 | 206 | 1976 |
| Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2‐microglobulin inactivation in MSI‐positive tumors and LMP7/TAP2 … CM Cabrera, P Jimenez, T Cabrera, C Esparza, F Ruiz‐Cabello, ... Tissue antigens 61 (3), 211-219, 2003 | 205 | 2003 |
| Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma AB Del Campo, JA Kyte, J Carretero, S Zinchencko, R Méndez, ... International journal of cancer 134 (1), 102-113, 2014 | 191 | 2014 |
| Mutations of the β2‐microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides R Benitez, D Godelaine, MA Lopez‐Nevot, F Brasseur, P Jimenez, ... Tissue antigens 52 (6), 520-529, 1998 | 185 | 1998 |
| MHC class I antigens and immune surveillance in transformed cells N Aptsiauri, T Cabrera, A Garcia‐Lora, MA Lopez‐Nevot, F Ruiz‐Cabello, ... International review of cytology 256, 139-189, 2007 | 177 | 2007 |
| HLA class I antigens in human tumors F Garrido, T Cabrera, MA Lopez-Nevot, F Ruiz-Cabello Advances in cancer research 67, 155-195, 1995 | 177 | 1995 |
